MedWatch

Novo Nordisk hires former Director General of DMA

Now-former Director General of the Danish Medicines Agency (DMA) Thomas Senderovitz will soon be spending his time at Novo Nordisk examining large amounts of data coming from the firm's clinical trials.

Photo: Stine Tidsvilde

When the now-former Director General of the Danish Medicines Agency (DMA) Thomas Senderovitz steps into his new role at Novo Nordisk in May, his main focus area will be clinical development, according to an email sent from Novo Nordisk to MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs